Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

Fig. 1

Baseline and post-treatment scores at week 12 across all Short Form 36 Health Survey domains. Baseline (BL) and SF-36 domain scores are relative to age- and gender-adjusted norms (A/G norms) for the general US population. a PBO. b UPA 15 mg. c UPA 30 mg. d Combined. In the combined spydergrams, most of the UPA 30-mg results are covered up by the UPA 15-mg results. BL values and SF-36 domain scores were re-scored from 0 to 100. No further transformations were applied for this analysis. BP, Bodily Pain; GH, General Health; MH, Mental Health; PBO, placebo; PF, Physical Functioning; RE, Role-Emotional; RP, Role-Physical; SF, Social Functioning; UPA, upadacitinib; VT, Vitality; Wk, week

Back to article page